Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Simcere Pharmaceutical Group Limited ( (HK:2096) ) has issued an announcement.
Simcere Pharmaceutical Group Limited announced that its 2024 annual cap for promotion service fees under its Exclusive Promotion Services Cooperation Agreement with Beijing Simcere Sanroad was exceeded by RMB5.2 million due to unexpectedly high sales of Fumarate Bedaquiline Tablets. To accommodate anticipated future sales growth, the company has revised its annual caps for 2025 and 2026, reflecting an upward adjustment based on market share estimates and past sales performance in the region.
More about Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is a Hong Kong-incorporated company operating in the pharmaceutical industry. The company focuses on the development and promotion of generic drugs, with a particular emphasis on innovative cancer treatments and other therapeutic areas.
YTD Price Performance: -3.24%
Average Trading Volume: 5,216,976
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: HK$17.08B
See more insights into 2096 stock on TipRanks’ Stock Analysis page.